{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-029010","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.071429+00:00","generated_at":"2026-05-26T01:54:55.876084+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025","bullets":["Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.","Cash and marketable securities $754.4M as of Dec 31, 2024; sufficient to fund operations into 2027.","Phase 3 X-TOLE2/3 azetukalner FOS topline data expected H2 2025; Phase 3 MDD and bipolar depression trials advancing.","CFO Sherry Aulin resigns effective June 30, 2025, for personal reasons; will advise through Aug 31, 2025.","Neurocrine collaboration milestone triggers $7.5M payment; Phase 1 study of Nav1.2/1.6 inhibitor initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-029010","json":"https://secwatch.observer/filing/0000950170-25-029010.json","markdown":"https://secwatch.observer/filing/0000950170-25-029010.md","text":"https://secwatch.observer/filing/0000950170-25-029010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/0000950170-25-029010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/xene-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:54:55.876084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be65d509f8","claim":"Sherry Aulin resigned as Chief Financial Officer at Xenon Pharmaceuticals Inc..","evidence_excerpt":"On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/0000950170-25-029010-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}